Bleeding Disorders
Conference Coverage
Monthly fitusiran showed promise in small phase I hemophilia trial
Monthly drug means good news for hemophilia A and B patients.
From the Journals
Prophylactic emicizumab cut bleeds by 87% in hemophilia A with inhibitors
The results of this phase III trial offer “an elegant new solution for treatment.”
News
Fostamatinib under review by FDA for chronic ITP
The US Food and Drug Administration (FDA) has accepted a new drug application (NDA) for the use of fostamatinib disodium (Tavalisse™) in the...
News
FDA approves Rebinyn for hemophilia B treatment
Rebinyn is intended to control and treat bleeding episodes, as well as provide perioperative management of bleeding.
News
FDA advisory committee supports L-glutamine for SCD
L-glutamine powder got the nod from the majority of the FDA’s Oncologic Drugs Advisory Committee for treatment of sickle cell disease.
Conference Coverage
Consider switch to clopidogrel for DAPT early post ACS
PARIS – TOPIC trial provides new evidence-based DAPT strategy.
Conference Coverage
Intensive BP lowering may reduce larger hematoma expansion in ICH
BOSTON – Intensive systolic blood pressure reduction did not significantly reduce hematoma expansion, except in those with larger hematomas.
News
EMA recommends drug receive orphan designation for PNH
The European Medicines Agency (EMA) has recommended orphan drug designation for the complement C3 inhibitor APL-2 as a treatment for paroxysmal...
Conference Coverage
Watchful waiting a suitable option for pediatric acute ITP
MONTREAL – Treatment of acute idiopathic thrombocytopenic purpura does not appear to increase risk of later chronic ITP, except in children up to...
Conference Coverage
Cord blood/placental cell combo induces rapid immune recovery
MONTREAL – The probability of 1-year survival in children with severe diseases requiring stem cell transplants was 81%.
From the Journals
FDA boxed warning leads to drop off in use of ESAs
The FDA warning language was linked with a sharp decrease in use of erythropoietin-stimulating agents in colorectal, breast, and lung cancer...